TNI BioTech Expands Partnership With Hubei Qianjiang Pharma
8/14/2014 2:18:49 PM
August 13, 2014 -- TNI BioTech of Florida expanded its relationship with Hubei Qianjiang Pharma (SHA: 600568) by signing an agreement that will speed up development of IRT-101 (MENK). TNI discovered MENK, an immunotherapy for cancer and autoimmune diseases. In 2012, Qianjiang in-licensed China rights to the drug. According to TNI, the partnership combines the drug development expertise of its subsidiary Cytocom, with Qianjiang’s financial, manufacturing and distribution capabilities. More details....
Help employers find you! Check out all the jobs and post your resume.
comments powered by